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Younsuck KohAbstract
Acute respiratory distress syndrome (ARDS) is characterized by permeability pulmonary edema and refractory
hypoxemia. Recently, the new definition of ARDS has been published, and this definition suggested severity-oriented
respiratory treatment by introducing three levels of severity according to PaO2/FiO2 and positive end-expiratory
pressure. Lung-protective ventilation is still the key of better outcome in ARDS. Through randomized trials, short-term
use of neuromuscular blockade at initial stage of mechanical ventilation, prone ventilation in severe ARDS, and
extracorporeal membrane oxygenation in ARDS with influenza pneumonia showed beneficial efficacy. However, ARDS
mortality still remains high. Therefore, early recognition of ARDS modified risk factors and the avoidance of aggravating
factors during the patient's hospital stay can help decrease its development. In addition, efficient antifibrotic strategies
in late-stage ARDS should be developed to improve the outcome.
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Acute respiratory distress syndrome (ARDS) is a perme-
ability pulmonary edema characterized by increased per-
meability of pulmonary capillary endothelial cells and
alveolar epithelial cells, leading to hypoxemia that is re-
fractory to usual oxygen therapy. In a national study in
Iceland, the incidence of ARDS almost doubled, but hos-
pital mortality decreased during the 23 years of observa-
tion [1]. In a prospective study in Spain, despite use of
lung-protective ventilation, overall ICU and hospital
mortality of ARDS patients is still higher than 40% [2].
The aim of this review is to provide an update on ARDS.Review
The evolution of the definition of ARDS
The first definition of ARDS dates to Ashbaugh and col-
leagues in 1967 [3], followed by the American-European
Consensus Conference's definition in 1994. The American-
European Consensus Conference's definition in 1994,
which has been challenged over the years in several studies
since the assessment of oxygenation defect, does not re-
quire standardized ventilatory support [4]. Recently, a new
consensus definition of ARDS, the Berlin definition, has
been published [5]. The new definition of ARDS maintains
a link to the 1994 definition with diagnostic criteria ofCorrespondence: yskoh@amc.seoul.kr
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stated.timing, chest imaging, origin of edema, and hypoxemia.
According to the revised definition of ARDS, a minimum
level of positive end-expiratory pressure (PEEP) and mutu-
ally exclusive PaO2/FiO2 thresholds was chosen to differen-
tiate between three levels of severity (mild, moderate, and
severe) of ARDS. The revised definition appears to have
improved predictive validity for mortality of its spectrum
of severity [5]. The revised definition presents a severity-
oriented method for respiratory management of ARDS [6].
Histopathological findings have been correlated to severity
and duration of ARDS [7]. Using clinical criteria, the re-
vised definition for ARDS allowed for the identification of
severe ARDS of more than 72 h as a homogeneous group
of patients characterized by a high proportion of diffuse al-
veolar damage [7].Pathogenesis of ARDS
In addition to the classical views of ARDS including the
role of cellular and humoral mediators, the role of the
renin-angiotensin system (RAS) has been highlighted.
The RAS is thought to contribute to the pathophysi-
ology of ARDS by increasing vascular permeability.
Angiotensin-converting enzyme (ACE) is a key enzyme
of the RAS that converts inactive angiotensin I to the
vasoactive and aldosterone-stimulating peptide angioten-
sin II and also metabolizes kinins along with many other
biologically active peptides. ACE is found in varying
levels on the surface of lung epithelial and endothelialis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
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thelial and endothelial cells and is a potent fibrogenic
factor [9]. Based on these biological properties of ACE,
there is considerable interest in its potential involvement
in acute lung injury (ALI)/ARDS [10,11].
Cor pulmonale in ARDS
Since the first publication demonstrating the presence of
pulmonary hypertension and elevated pulmonary vascu-
lar resistance in patients with severe acute respiratory
failure [12], the development of acute cor pulmonale in
ARDS has been considered a poor prognostic factor. In
two recent prospective observational studies, cor pulmo-
nale occurrence was not negligible (up to one fourth) in
ARDS patients ventilated with airway pressure limita-
tions, was associated with sepsis, and was a risk factor
for 28-day mortality [13,14]. Considering these findings
together with the association of high PEEP levels and
elevated plateau pressure with pulmonary artery pres-
sure [15], careful monitoring of acute cor pulmonale is
recommended in ARDS.
Diagnosis and early intervention
Differential diagnosis between cardiogenic pulmonary
edema (CPE) and ARDS is sometimes not easy. The
accuracy of the portable chest radiograph to detect pul-
monary abnormalities consistent with ARDS is signifi-
cantly limited [16]. In a study using chest computed
tomography, upper-lobe-predominant ground-glass at-
tenuation, central-predominant ground-glass attenu-
ation, and central airspace consolidation were associated
with high positive predictive values (95.2%, 92.3%, and
92.0%, respectively) and moderate negative predictive
values (47.5%, 51.4%, and 50.0%, respectively) to diag-
nose CPE [17]. Measurement of the extravascular lung
water index and the pulmonary vascular permeability
index (PVPI) [18] using a transpulmonary thermodilu-
tion method seemed to be a useful quantitative diagnos-
tic tool for ARDS in patients with hypoxemic respiratory
failure and radiologic infiltrates. In one study, A PVPI
value of 2.6–2.85 provided a definitive diagnosis of ALI/
ARDS (specificity, 0.90–0.95), and a value <1.7 ruled out
an ALI/ARDS diagnosis (specificity, 0.95) [18].
Clinical trials of anti-inflammatory therapy
Although ARDS is an acute lung inflammation in which
diverse inflammatory cells and mediators are involved,
multiple anti-inflammatory interventions have not shown
improved survival. Clinical trials using corticosteroids,
prostaglandins, nitric oxide, prostacyclin, surfactant, liso-
fylline, ketoconazole, N-acetylcysteine, and fish oil have
been unable to show a statistically significant improve-
ment in patient mortality. The use of corticosteroids to
attenuate inflammation remains controversial. Moreover,the ARDSnet study of steroid treatment [19] revealed
that administration after 14 days of disease onset could
be harmful. Up to now, the efficacy of low-dose cortico-
steroids [20] for the alleviation of inflammation, to re-
duce organ dysfunction and to improve survival,
especially in sepsis associated ARDS, has not been fully
elucidated.
Mechanical ventilation
Numerous lines of evidence have demonstrated that in-
appropriate mechanical ventilatory settings can produce
further lung damage to patients with ARDS. Ventilator-
induced lung injury seems to be attributed to end-
inspiratory overdistension and a low end-expiratory lung
volume, allowing repeated collapse and re-expansion with
each respiratory cycle (tidal recruitment). Tidal recruitment
results in high shear force on alveolar walls and small air-
ways during inflation, especially at the interfaces between
collapsed and aerated alveoli. Therefore, low tidal volume
(6 mL/kg of predicted body weight), limitation of plateau
pressure (less than 28–30 cm H2O), and appropriate PEEP
is a key component of a lung-protective ventilatory strategy
(LPVS) [21]. Since then, the lung-protective mechanical
ventilation strategy has been the standard practice for the
management of ARDS. In a retrospective observational
study of 104 patients with ARDS caused by pandemic influ-
enza A/H1N1 infection admitted to 28 ICUs in South
Korea, low-tidal volume (TV) mechanical ventilation still
benefited patients with ARDS caused by viral pneumonia.
Patients with TV less than or equal to 7 mL/kg required
ventilation, ICU admission, and hospitalization for fewer
days than those with TV greater than 7 mL/kg (11.4 vs.
6.1 days for 28-day ventilator-free days, 9.7 vs. 4.9 days for
28-day ICU-free days, and 5.2 vs. 2.4 days for 28-day
hospital-free days, respectively). A tidal volume greater
than 9 mL/kg (hazard ratio, 2.459; P = 0.003) and the Se-
quential Organ Failure Assessment score (hazard rate,
1.158; P = 0.014) were significant predictors of 28-day ICU
mortality [22].
The lung-protective ventilation strategy is both safe
and potentially beneficial in patients who do not have
ARDS at the onset of mechanical ventilation. In mech-
anically ventilated patients without ARDS at the time of
endotracheal intubation, the majority of data favors
lower tidal volume to reduce progression to ARDS [23].
Septic patients without ARDS who were ventilated
with a protective strategy using a plateau pressure <30
cmH2O showed better outcomes and a lower incidence
of ARDS than those ventilated without this limit on
plateau pressure [24]. A recent meta-analysis also showed
that protective ventilation with low tidal volumes was as-
sociated better clinical outcomes even in patients without
ARDS [25]. The use of very low TV combined with extra-
corporeal CO2 removal has the potential to further reduce
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will improve survival in ARDS patients remains to be de-
termined [26].
To select the optimal PEEP level to prevent the
undesirable tidal recruitment together with the mini-
mization of alveolar overdistension is not easy. Tradition-
ally, the level of PEEP has been set according to the
required level of FiO2. Simple elevation of the PEEP level
which is more than that of the ARDSnet clinical trial group
of low TV was shown to not improve clinical outcome
[27]. Another way to set the PEEP level is to employ a dec-
remental PEEP trial after alveolar recruitment maneuvers
(ARM). An ARM has the advantage of standardizing the
history of lung volume and to let the lung remain more
open at the end of expiration. However, the application of
early ARM with low tidal volume has not been proved effi-
cacious for the reduction of mortality [28,29]. The PEEP
level could be set according to a level of transpulmonary
pressure during expiration. One study demonstrated the ef-
ficacy of esophageal pressure-guided PEEP on the improve-
ment of oxygenation and lung compliance in ALI [30]. The
researchers set the PEEP at a level to guarantee that trans-
pulmonary pressure during end-expiratory occlusion would
stay between 0 and 10 cm H2O as well as keep transpul-
monary pressure during end-inspiratory occlusion at less
than 25 cm H2O [30]. A problem with setting the PEEP ac-
cording to the transpulmonary pressure is the technical dif-
ficulty in achieving accurate esophageal pressure using an
esophageal balloon catheter [31]. Recently, electrical imped-
ance tomography has been introduced as a true bedside
technique, which provides information on regional ventila-
tion distribution [32].
Prone ventilation
Prone position reduces the transpulmonary pressure gra-
dient, recruiting collapsed regions of the lung without
increasing airway pressure or hyperinflation. Prone ven-
tilation showed improved oxygenation and improved
outcomes in severe hypoxemic patients with ARDS [33].
Prone ventilation was more effective in obese patients
with ARDS than in non-obese ARDS patients [34]. In a
study investigating whether there is any interdependence
between the effects of PEEP and prone positioning,
prone positioning further decreased non-aerated tissue
(322 ± 132 to 290 ± 141 g, P = 0.028) and reduced tidal
hyperinflation observed at PEEP 15 in the supine pos-
ition (0.57% ± 0.30% to 0.41% ± 0.22%) [35]. Cyclic re-
cruitment/de-recruitment only decreased when high
PEEP and prone positioning were applied together
(4.1% ± 1.9% to 2.9% ± 0.9%, P = 0.003), especially in pa-
tients with high lung recruitability [35]. These results
showed that prone ventilation decreases alveolar in-
stability and hyperinflation observed at high PEEP in
ARDS patients.Extracorporeal membrane oxygenation and high-frequency
oscillatory ventilation for ARDS
Extracorporeal membrane oxygenation (ECMO) is a ther-
apy that has been used in severe cases of ARDS when pa-
tients fail to improve with traditional management. Major
technological improvements in ECMO machines and the
positive results of the conventional ventilatory support
versus extracorporeal membrane oxygenation for severe
adult respiratory failure (CESAR) trial [36] have reignited
interest in veno-venous ECMO in patients with severe
ARDS. Recent literature shows varying mortality rates for
the use of ECMO for ARDS. Although transfer of patients
to an ECMO center for treatment using specific criteria
and indications may improve outcomes, credible evidence
supporting a mortality benefit of ECMO is lacking. Fur-
ther research is needed regarding the timing of the initi-
ation of ECMO, the standardization of therapy and
monitoring, and understanding which type of ECMO re-
duces morbidity and mortality rates in patients with
ARDS.
High-frequency oscillatory ventilation (HFOV) seems
ideal for lung protection in acute respiratory distress
syndrome. HFOV was effective in improving oxygen-
ation in adults with ARDS, particularly when instituted
early [37]. Changes in PaO2/FiO2 during the first 3 h of
HFOV helped identify patients that are more likely to
survive [37] and showed a promising outcome compared
with ARDS patients without current LPVS [38]. In
adults with moderate-to-severe ARDS, early application
of HFOV compared with an employment of a ventilation
strategy of low tidal volume and high positive end-
expiratory pressure, does not reduce, and may increase,
in-hospital mortality [39].
Neuromuscular blockade and sedation
Neuromuscular blocking agents (NMBAs) are commonly
used in ARDS, but the benefits and the risks of using these
agents are controversial. In a recent randomized trial [40],
the use of NMBAs in ARDS patients showed a beneficial
outcome. In addition, short-term infusion of cisatracurium
besylate reduced hospital mortality and barotrauma and
did not appear to increase ICU-acquired weakness for crit-
ically ill adults with ARDS [40]. The use of alpha-2 adren-
ergic agonists (e.g., dexmedetomidine) could be used in a
non-invasive positive pressure ventilation trial in a select
group of ARDS patients, as this class of drugs preserve re-
spiratory drive [41], lower oxygen consumption, and pul-
monary hypertension and increase diuresis.
Fluid management and a bronchodilator use
Because vascular and epithelial permeability is increased
in ARDS, fluid management is one of the most difficult
measures to manage in septic shock patients with ARDS.
A conservative fluid management strategy maintaining a
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the need for fewer days of mechanical ventilation com-
pared with a liberal fluid management strategy in ARDS
[42]. However, conservative fluid management is highly
recommended after hemodynamic stabilization in ARDS
patients. In hemodynamically unstable patients, dynamic
monitoring of lung fluid balance needs to be imple-
mented to guide the administration of fluids in ARDS
patients [43]. Despite a putative beneficial role in the
resolution of alveolar edema seen in preliminary studies,
recent evidence has indicated significant detrimental
effects associated with beta-2 agonist use in ARDS
patients [44].
Experimental trials
In experimental models of ARDS mesenchymal stem
cells (MSCs), transplantation improved the regeneration
of lung tissue [45,46]. The benefits of these MSCs are
derived not only from the incorporation of these cells in
the damaged lung, but also from their interaction with
damaged lung cells and immunologic modulation [47].
MSCs can also control oxidative stress, transfer func-
tional mitochondria to the damaged cells, and control
bacterial infection by secreting antibacterial peptides
[48]. Most of these studies administered MSCs as a pre-
treatment, and the use of MSCs is still highly experi-
mental as a treatment or prevention strategy of ARDS.
Prognosis and quality of life of survivors from ARDS
In a meta-analysis, an insertion/deletion (I/D) polymorph-
ism in the ACE gene was not associated with susceptibility
to ALI/ARDS for any genetic model. However, the ACE I/
D polymorphism was associated with an increased mortal-
ity risk of ALI/ARDS in Asian subjects [49]. After correct-
ing for multiple comparisons, this finding remained
significant, and it was shown that the genotype of the I/D
polymorphism in ACE may be a predictor of ALI/ARDS
mortality in Asian populations [49].
Along with high mortality risks, survivors suffer sig-
nificant decrements in their quality of life [50]. In survi-
vors of acute lung injury, there was no difference in
physical function, survival, or multiple secondary out-
comes at 6 and 12 months follow-up after initial trophic
or full enteral feeding [51].
Conclusions
Currently, in spite of the remarkable advancements in the
understanding of its pathogenesis, the only effective thera-
peutic measure to decrease mortality is low-tidal volume
mechanical ventilation and prone ventilation for severe
ARDS cases. In extreme, life-threatening cases, ECMO
seems to serve as a bridge to recovery and enables lung-
protective ventilation. Most ARDS patients die of multi-
organ failure rather than irreversible respiratory failure,indicating that ARDS is closely associated with other
organs by neurological, biochemical, metabolic, and in-
flammatory reactions. Moreover, the lungs may play an
important role in the development of non-pulmonary
organ failure in ARDS. Thus, early recognition of ARDS
modified risk factors and the avoidance of aggravating fac-
tors during the patient's hospital stay (e.g., non-protective
mechanical ventilation, multiple blood product transfu-
sions, positive fluid balance, ventilator-associated pneumo-
nia, and gastric aspiration) can help decrease its incidence.
In addition, efficient antifibrotic strategies are still lacking
for patients with late-stage ARDS. Therefore, new therap-
ies that address the underlying pathophysiology are
needed to reduce the mortality of patients with ARDS.
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